[Retracted] KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma

Figure 1

Evolution of MEK inhibitor-resistant in UM cells. The CCK8 assay of cell viability in 92.1 parental (92.1-P) or 92.1-resistant (92.1-R) cells treated with Tra with indicated concentrations for 72 h (a) or indicated times with Tra (5 μM) (b). CCK8 analysis of cell viability in OMM1 parental (OMM1-P) or OMM1 resistant (OMM1-R) cells treated with Tra with indicated concentrations for 72 h (c) or indicated times with Tra (5 μM) (d). (e) Western blot detection of the phosphorylation level of ERK1/2 in OMM1-P and OMM1-R cells treated with Tra (5 μM) for 24 h. (f) Quantitative analysis of p-ERK1/2 ratio to β-actin. (g) Western blot detection of the phosphorylation level of Akt (T308) in OMM1-P and OMM1-R cells treated with indicated concentrations of Tra for 24 h. (h) Quantitative analysis of p-Akt (T308) ratio to β-actin. ; two-way analysis of variance (ANOVA) in (a–d and h); one-way analysis of variance (ANOVA) in (f).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)